Global Liposome Development Service 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI03250336

Publication Date:

March 18, 2025

Pages:

139

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Liposome Development Service market size is predicted to grow from US$ 1191 million in 2024 to US$ 1928 million in 2030; it is expected to grow at a CAGR of 8.4% from 2024 to 2030.
Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.
麻豆原创 Driver
The liposome development service market is driven by the growing demand for advanced drug delivery systems that enhance the bioavailability, efficacy, and safety of therapeutics. Liposomes, being biocompatible and capable of targeted drug delivery, are increasingly used in the development of treatments for cancer, infectious diseases, and vaccines. Additionally, the rise in biologics and personalized medicine, coupled with advancements in nanotechnology, supports the growth of the liposome development service market.
麻豆原创 Challenge
Despite its potential, the liposome development service market faces challenges such as high production costs and complex manufacturing processes that require specialized expertise and facilities. Regulatory hurdles in the approval of liposome-based therapies and the potential for stability issues during storage and transportation further constrain the market's growth. These factors create barriers, particularly for smaller companies with limited resources.
Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.
The 鈥淟iposome Development Service Industry Forecast鈥� looks at past sales and reviews total world Liposome Development Service sales in 2023, providing a comprehensive analysis by region and market sector of projected Liposome Development Service sales for 2024 through 2030. With Liposome Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome Development Service industry.
This Insight Report provides a comprehensive analysis of the global Liposome Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Liposome Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Liposome Development Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome Development Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome Development Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposome Development Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Liposomes
Lipid Nanoparticles
Segmentation by Application:
Preclinical
Clinical
Commercial
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Liposome Development Service 麻豆原创 Size 2019-2030
2.1.2 Liposome Development Service 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Liposome Development Service by Country/Region, 2019, 2023 & 2030
2.2 Liposome Development Service Segment by Type
2.2.1 Liposomes
2.2.2 Lipid Nanoparticles
2.3 Liposome Development Service 麻豆原创 Size by Type
2.3.1 Liposome Development Service 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Liposome Development Service 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Liposome Development Service Segment by Application
2.4.1 Preclinical
2.4.2 Clinical
2.4.3 Commercial
2.5 Liposome Development Service 麻豆原创 Size by Application
2.5.1 Liposome Development Service 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Liposome Development Service 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Liposome Development Service 麻豆原创 Size by Player
3.1 Liposome Development Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Liposome Development Service Revenue by Player (2019-2024)
3.1.2 Global Liposome Development Service Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Liposome Development Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Liposome Development Service by Region
4.1 Liposome Development Service 麻豆原创 Size by Region (2019-2024)
4.2 Global Liposome Development Service Annual Revenue by Country/Region (2019-2024)
4.3 Americas Liposome Development Service 麻豆原创 Size Growth (2019-2024)
4.4 APAC Liposome Development Service 麻豆原创 Size Growth (2019-2024)
4.5 Europe Liposome Development Service 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Liposome Development Service 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Liposome Development Service 麻豆原创 Size by Country (2019-2024)
5.2 Americas Liposome Development Service 麻豆原创 Size by Type (2019-2024)
5.3 Americas Liposome Development Service 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposome Development Service 麻豆原创 Size by Region (2019-2024)
6.2 APAC Liposome Development Service 麻豆原创 Size by Type (2019-2024)
6.3 APAC Liposome Development Service 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Liposome Development Service 麻豆原创 Size by Country (2019-2024)
7.2 Europe Liposome Development Service 麻豆原创 Size by Type (2019-2024)
7.3 Europe Liposome Development Service 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposome Development Service by Region (2019-2024)
8.2 Middle East & Africa Liposome Development Service 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Liposome Development Service 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Liposome Development Service 麻豆原创 Forecast
10.1 Global Liposome Development Service Forecast by Region (2025-2030)
10.1.1 Global Liposome Development Service Forecast by Region (2025-2030)
10.1.2 Americas Liposome Development Service Forecast
10.1.3 APAC Liposome Development Service Forecast
10.1.4 Europe Liposome Development Service Forecast
10.1.5 Middle East & Africa Liposome Development Service Forecast
10.2 Americas Liposome Development Service Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Liposome Development Service Forecast
10.2.2 Canada 麻豆原创 Liposome Development Service Forecast
10.2.3 Mexico 麻豆原创 Liposome Development Service Forecast
10.2.4 Brazil 麻豆原创 Liposome Development Service Forecast
10.3 APAC Liposome Development Service Forecast by Region (2025-2030)
10.3.1 China Liposome Development Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Liposome Development Service Forecast
10.3.3 Korea 麻豆原创 Liposome Development Service Forecast
10.3.4 Southeast Asia 麻豆原创 Liposome Development Service Forecast
10.3.5 India 麻豆原创 Liposome Development Service Forecast
10.3.6 Australia 麻豆原创 Liposome Development Service Forecast
10.4 Europe Liposome Development Service Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Liposome Development Service Forecast
10.4.2 France 麻豆原创 Liposome Development Service Forecast
10.4.3 UK 麻豆原创 Liposome Development Service Forecast
10.4.4 Italy 麻豆原创 Liposome Development Service Forecast
10.4.5 Russia 麻豆原创 Liposome Development Service Forecast
10.5 Middle East & Africa Liposome Development Service Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Liposome Development Service Forecast
10.5.2 South Africa 麻豆原创 Liposome Development Service Forecast
10.5.3 Israel 麻豆原创 Liposome Development Service Forecast
10.5.4 Turkey 麻豆原创 Liposome Development Service Forecast
10.6 Global Liposome Development Service Forecast by Type (2025-2030)
10.7 Global Liposome Development Service Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Liposome Development Service Forecast
11 Key Players Analysis
11.1 Precision NanoSystems
11.1.1 Precision NanoSystems Company Information
11.1.2 Precision NanoSystems Liposome Development Service Product Offered
11.1.3 Precision NanoSystems Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Precision NanoSystems Main Business Overview
11.1.5 Precision NanoSystems Latest Developments
11.2 Evonik
11.2.1 Evonik Company Information
11.2.2 Evonik Liposome Development Service Product Offered
11.2.3 Evonik Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Evonik Main Business Overview
11.2.5 Evonik Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Liposome Development Service Product Offered
11.3.3 Merck KGaA Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Genevant Sciences
11.4.1 Genevant Sciences Company Information
11.4.2 Genevant Sciences Liposome Development Service Product Offered
11.4.3 Genevant Sciences Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Genevant Sciences Main Business Overview
11.4.5 Genevant Sciences Latest Developments
11.5 Exelead
11.5.1 Exelead Company Information
11.5.2 Exelead Liposome Development Service Product Offered
11.5.3 Exelead Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Exelead Main Business Overview
11.5.5 Exelead Latest Developments
11.6 Avanti Polar Lipids
11.6.1 Avanti Polar Lipids Company Information
11.6.2 Avanti Polar Lipids Liposome Development Service Product Offered
11.6.3 Avanti Polar Lipids Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Avanti Polar Lipids Main Business Overview
11.6.5 Avanti Polar Lipids Latest Developments
11.7 Nippon Fine Chemical
11.7.1 Nippon Fine Chemical Company Information
11.7.2 Nippon Fine Chemical Liposome Development Service Product Offered
11.7.3 Nippon Fine Chemical Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Nippon Fine Chemical Main Business Overview
11.7.5 Nippon Fine Chemical Latest Developments
11.8 Lipoid
11.8.1 Lipoid Company Information
11.8.2 Lipoid Liposome Development Service Product Offered
11.8.3 Lipoid Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Lipoid Main Business Overview
11.8.5 Lipoid Latest Developments
11.9 Polymun Scientific
11.9.1 Polymun Scientific Company Information
11.9.2 Polymun Scientific Liposome Development Service Product Offered
11.9.3 Polymun Scientific Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Polymun Scientific Main Business Overview
11.9.5 Polymun Scientific Latest Developments
11.10 Corden Pharma
11.10.1 Corden Pharma Company Information
11.10.2 Corden Pharma Liposome Development Service Product Offered
11.10.3 Corden Pharma Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Corden Pharma Main Business Overview
11.10.5 Corden Pharma Latest Developments
11.11 Acuitas Therapeutics
11.11.1 Acuitas Therapeutics Company Information
11.11.2 Acuitas Therapeutics Liposome Development Service Product Offered
11.11.3 Acuitas Therapeutics Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Acuitas Therapeutics Main Business Overview
11.11.5 Acuitas Therapeutics Latest Developments
11.12 Creative Biolabs
11.12.1 Creative Biolabs Company Information
11.12.2 Creative Biolabs Liposome Development Service Product Offered
11.12.3 Creative Biolabs Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Creative Biolabs Main Business Overview
11.12.5 Creative Biolabs Latest Developments
11.13 Creative Biostructure
11.13.1 Creative Biostructure Company Information
11.13.2 Creative Biostructure Liposome Development Service Product Offered
11.13.3 Creative Biostructure Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Creative Biostructure Main Business Overview
11.13.5 Creative Biostructure Latest Developments
11.14 T&T Scientific
11.14.1 T&T Scientific Company Information
11.14.2 T&T Scientific Liposome Development Service Product Offered
11.14.3 T&T Scientific Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 T&T Scientific Main Business Overview
11.14.5 T&T Scientific Latest Developments
11.15 FormuMax Scientific
11.15.1 FormuMax Scientific Company Information
11.15.2 FormuMax Scientific Liposome Development Service Product Offered
11.15.3 FormuMax Scientific Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 FormuMax Scientific Main Business Overview
11.15.5 FormuMax Scientific Latest Developments
11.16 PlantaCorp
11.16.1 PlantaCorp Company Information
11.16.2 PlantaCorp Liposome Development Service Product Offered
11.16.3 PlantaCorp Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 PlantaCorp Main Business Overview
11.16.5 PlantaCorp Latest Developments
11.17 CD Bioparticles
11.17.1 CD Bioparticles Company Information
11.17.2 CD Bioparticles Liposome Development Service Product Offered
11.17.3 CD Bioparticles Liposome Development Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 CD Bioparticles Main Business Overview
11.17.5 CD Bioparticles Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.